Étiquette : Infectious diseases

ERBC GROUP

by jbertholdin Institutions, Service Providers & others

ERBC GROUP

About the company

ERBC group is a leader in discovery and non-clinical studies, offering to healthcare and chemical professionals a comprehensive range of discovery and preclinical models, regulatory pre-IND package and consultancy services to de-risk innovation and improve R&D productivity.

About the solution

At ERBC Group, THEY STRATEGIZE your approach to make your drug development a SUCCESS:
– Build on most relevant translational models
– Select best predictive biomarkers
– Choose state-of-the-art technologies.

Website
Key information

–  Therapeutic areas: Oncology – Cancer, Immunology, Inflammation, Neurology – Neurosciences, Cell and gene therapies, Cardiovascular, Infectious diseases, Metabolic diseases – Hepatology – Diabetes, Gastroenterology, Respiratory, Ophthalmology, Allergy, Dermatology, Orthopedics, Central nervous system, Nephrology, Cardiology, Pulmonology, Endocrinology, Hematology

–  Based in: Baugy, Toulouse, Lyon, Orleans (FRANCE)

–  Employees: 201-500

–  Created in: 2019

OXELTIS

by jbertholdin Institutions, Service Providers & others

OXELTIS

About the company

Oxeltis is a medicinal chemistry services company created in 2010 in Montpellier, France, by former researchers from Idenix Pharmaceuticals (formerly MSD). The company has a small-scale custom synthesis business and hit and lead optimization services in various areas, such as antivirals, antibiotics, and anticancer compounds. Oxeltis’ scientific team comprises 21 experienced chemists with recognized expertise in specific areas of organic synthesis: heterocycles, macrocycles, nucleosides/nucleotides, phosphoramidites, iminosugars, modified sugars, oligosaccharides, and PROTACs. Oxeltis services includes also route scouting and up to 50-100g synthesis. Oxeltis works with European, Japanese, and North American start-ups, pharma companies, and research institutions.

About the solution

Oxeltis team is focused on speed of delivery, quality, and confidentiality of the services and collaborations it develops. Oxeltis has completed more than 35 projects with complex and multi-step synthetic chemistry for pharmaceutical and biotechnology companies, including five of the ten largest global pharmaceutical companies. Several drug candidates delivered to its customers are in clinical development.

Website
Key information

–  Therapeutic areas: Infectious diseases, antivirals, antibacterials, Oncology, Neurology, CNS

–  Based in: Montpellier (FRANCE)

–  Employees: 11 – 50

–  Created in: 2010

MABSILICO

by jbertholdin Biotech, Pharma

MABSILICO

About the company

MAbSilico is the TechBio pionner company specializing in computational solutions for discovering and designing therapeutic antibodies. Their solutions leverages artificial intelligence (AI) and machine learning to characterize, optimize and design therapeutic antibodies.

MAbSilico’s platform aims to accelerate the antibody discovery process by structural design with epitope-driven and multiparametric approaches. This allows to design highly effective antibodies, saving time and resources compared to traditional methods. We provide fully characterized antibodies against a target within 21 days that are internally validated with wet lab assays, leading to faster development of life-saving antibody therapies.

About the solution

MAbSilico uses a combination of 3D modeling, interaction simulation, and sequence analysis to identify promising antibody candidates after assessing for various factors, including their binding target (epitope), affinity, potential off-target effects, and developability.

While the solutions can be applied to antibody characterization, optimization and design, MAbSilico does not need to generate biological data to apply their solutions.

Integrating multi-parameters for the antibody design and validating the newly sequence with state of the art biological assays, MAbSilico is pioneering a game-changing approach to antibody discovery with internal discovery pipeline.

Website
Key information

–  Therapeutic areas: Computational antibody design & discovery applied in oncology, Immuno-oncology, Infectious diseases, Rare diseases

–  Based in: Tours & Paris (FRANCE)

–  Employees: 11 – 50

–  Created in: 2017

ANTABIO

by jbertholdin Biotech, Pharma

ANTABIO

About the company

Antabio is a privately-held clinical stage biopharmaceutical company developing novel and highly differentiated antibacterial treatments of drug-resistant infections due to WHO critical priority pathogens, with a particular focus on life-threatening respiratory infections.

Antabio has one of the best teams in the industry featuring former management and executives from Novexel, GSK, Merck and AstraZeneca with track-records in anti-infective drug development, licensing and M&A. The company has an impressive track-record in attracting non-dilutive funding, including multi-million € awards from the Wellcome Trust, CARB-X, the French Government (ARPEGE), and the European Union (EIC Accelerator).

About the solution

Antabio’s portfolio includes MEM-ANT3310, which combines the well-known carbapenem meropenem (MEM) with ANT3310, Antabio’s breakthrough serine-beta-lactamase (SBL) inhibitor. MEM-ANT3310 provides a unique coverage of priority Gram-negative pathogens frequently encountered in life-threatening infections such as Hospital-Acquired and Ventilator-Associated Pneumonia (HAP/VAP). Phase 1a clinical study has recently been completed.

Their portfolio also includes ANT3273, a groundbreaking (novel class, novel mode of action) inhaled drug targeting the LasB elastase of Pseudomonas aeruginosa (PA), a key virulence factor associated with increased lung pathology severity and worse outcomes in PA-infected patients, such as bronchiectasis, cystic fibrosis, asthma and COPD.

Website
Key information

–  Therapeutic areas: Infectious diseases, Urinary Tract Infection, Respiratory Tract Infection, Multidrug resistant infection, Bacterial infection, Gram negative bacterium infection, Lung infection, Bacterial Pneumonia, Bronchiectasis, Cystic Fibrosis

–  Based in: Labège (FRANCE)

–  Employees: 11 – 50

–  Created in: 2009

TRUFFLE CAPITAL

by jbertholdin Biotech, Pharma

TRUFFLE CAPITAL

About the company

For 20 years, Truffle Capital has been financing innovations, growing and empowering technology leaders in healthcare & finance.

Website
Key information

–  Therapeutic areas: Infectious diseases, oncology, rheumatalogy, joint diseases, Transplants

–  Based in: Paris (FRANCE)

–  Employees: 11 – 50

–  Created in: 2001

FABENTECH

by jbertholdin Biotech, Pharma

FABENTECH

About the company

Headquartered in Lyon, France, Fabentech, established in 2009, is a leading biopharmaceutical company specializing in the development and production of emergency treatments to combat the most critical biological threats to public health. Their innovative Fabshield® platform is a safe and fully validated polyclonal antibody technology aiming to produce highly purified polyclonal antibodies capable of neutralizing viruses, toxins, and their potential variants, thereby halting disease progression.

Fabentech’s mission is to collaborate closely with governments and healthcare organizations, delivering timely and effective medical countermeasures to address bioterrorism agents and emerging infectious diseases during emergency situations. Their integrated R&D capabilities and proprietary manufacturing site enable them to rapidly deploy biodefense and pandemic preparedness solutions against diverse targets, ensuring reliable protection and treatment options in the face of escalating risks.

About the solution

Fabentech’s produces broad-spectrum polyclonal antibodies that have proven to be effective against rapidly mutating pathogens or toxins with multiple variants.

FABENTECH has the largest pipeline of medical countermeasures in Europe for:
– Biodefense
– FBT-002, antitoxin program funded by the French Army against a plant-based toxin. Late-stage clinical phase with MA planned in 2025
– FBT-003, antitoxin program funded by the European Defense Fund. Status: PoC
– FBT-004, undisclosed antitoxin program.
– Antivirals
– Nipah virus infections, status: PoC
– Pan-sarbevovirus infections, status: discovery
– FabenFlu® a fully developed treatment against H5N1 avian flu with ODD status in Europe

Website
Key information

–  Therapeutic areas: Infectious Diseases, Intoxications, Biodefense

–  Based in: Lyon (FRANCE)

–  Employees: 11 -50

–  Created in: 2009

CYNBIOSE

by jbertholdin Biotech, CRO/CDMO, Pharma

CYNBIOSE

About the company

Cynbiose is a preclinical CRO specialized in non-human primate (NHP) translational models for biomedical research since 2008. They maintain a France-based AAALAC-accredited animal facility for toxicological studies. Their brand new state-of-the-art facility can also accommodate studies requiring biosafety environments from ABSL-1 to 3, as well as GMOs such as viral vector-based gene therapies.

About the solution

The NHP model is well suited to predict pharmacokinetic and pharmacodynamic parameters, guide the selection of a safe starting dose for FIH trials, and provide valuable data on the potential toxicity of the candidate.

Their non-GLP preclinical services include:

– Pharmacokinetics (PK, central pharmacokinetics) and pharmacodynamics (PD) profiles

– In vivo biodistribution studies: biodistribution pattern (tissues, fluids such as CSF), Kpuu determination, and non-invasive imaging technologies

– Preclinical safety assessment, DRF, MTD, immunotoxicity, immunogenicity studies

– Immunopharmacology models

– Dedicated solutions: Nose-to-brain delivery strategies, Inhaled products, Gene therapies

Their state-of-the-art France-based animal facility has been AAALAC accredited since 2015. Their proven platform can operate studies in biosafety levels up to level 3, as well as GMOs C1-2, in a GLP-like environment.

Cynbiose combines ten years of preclinical experience and a wide range of cutting-edge capabilities to serve biopharmaceutical companies. Driven by passion and curiosity for science, their sponsors value them as trusted, reliable, flexible, and innovative partners.

Website
Key information

–  Therapeutic areas: Central nervous system (CNS), Oncology, Infectious diseases, Respiratory diseases, Immune disorders & inflammation

–  Based in: Marcy l’Etoile (FRANCE)

–  Employees: 11 -50

– Created in: 2008

HORIANA

by jbertholdin Biotech, Institutions, Service Providers & others, Pharma

HORIANA

About the company

HORIANA is a premier consulting company dedicated to epidemiology and biostatistics, specializing in designing and conducting Healthcare Real-World Studies.

Established by a team of seasoned experts, each with over 15 years of experience in Life Sciences, Horiana is at the forefront of providing comprehensive support to its clients. With a dedicated team of more than 25 experts, Horiana is well-positioned to assist clients at every phase of their projects. Their clients span both private and public/academic healthcare professionals.

At HORIANA, they are committed to excellence and quality, ensuring the success of their clients’ projects.

About the solution

Their main solutions are:

– Expertise and Consulting: Specialized guidance in epidemiology, pharmacoepidemiology, and biostatistics/data science.
– Clinical and Observational Studies (on primary and secondary)
– Enriched Studies: Integration of data from diverse sources through multisource studies and linked studies.
– Evidence Synthesis: Conducting External Comparators such as Network Meta-Analysis (NMA) and Matching-Adjusted Indirect Comparison (MAIC).
– Synthetic Control Groups: Implementation of Synthetic Control Groups and External Control Arms.
– Training Programs: Certified QUALIOPI training center in Statistics & Epidemiology
– IDMC, DSMB and Strategic consulting

Website
Key information

–  Therapeutic areas: Biostatistics, Epidemiology & Data Science provider

–  Based in: Bordeaux, Grenoble (FRANCE) San Francisco (US)

–  Employees: 11 – 50

– Created in: 2021

IKTOS

by jbertholdin Biotech, Digital Health, Pharma

IKTOS

About the company

Incorporated in October 2016, Iktos is a French start-up company specialized in the development of artificial intelligence solutions applied to chemical research, more specifically medicinal chemistry and new drug design.

Iktos is developing a proprietary and innovative solution based on deep generative models, which enables, using existing data, to design molecules that are optimized in silico to meet all the success criteria of a small molecule discovery project.

The use of Iktos technology enables major productivity gains in upstream pharmaceutical R&D. Iktos offers its technology through the SaaS software platforms Makya™ for generative drug design and Spaya™ for retrosynthesis, and through strategic collaborations with pharma companies where Iktos mobilizes its unique platform and leading-edge capabilities to expedite small molecule drug discovery for the benefit of its partners. Iktos is also developing Iktos Robotics, a unique AI-driven synthesis automation platform which dramatically accelerates the Design-Make-Test cycle in drug discovery.

About the solution

Iktos offers its technology through the SaaS software platforms Makya™ for generative drug design and Spaya™ for retrosynthesis, and through strategic collaborations with pharma companies where Iktos mobilizes its unique platform and leading-edge capabilities to expedite small molecule drug discovery for the benefit of its partners. Iktos is also developing Iktos Robotics, a unique AI-driven synthesis automation platform which dramatically accelerates the Design-Make-Test cycle in drug discovery.

Iktos offers the possiblity to its partners to use it unique technology via proprietary SaaS software platforms: Makya for de novo generative design and Spaya for retrosynthesis and synthetic access. Its partners can also rely on Iktos expertise to run integrated drug discovery projects from hit discovery, hit-to-lead, lead optimization, all the way down to preclinical drug candidate.

Website
Key information

–  Therapeutic areas: Any therapeutic areas including oncology, CNS / neurology, Immunology, Infectious diseases, Rare diseases

–  Based in: Headquarters and lab: Paris (FRANCE)
Additional offices: US and JAPAN

–  Employees: 51 – 200

– Created in: 2016

CONTACT
Bose AvirupChief Business Officer

avirup.bose@iktos.com